| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P50 | author | Jennifer L Griggs | Q80975418 |
| P2093 | author name string | Christina H Jagielski | |
| Christopher G Greenman | |||
| P2860 | cites work | Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 | Q29614193 |
| Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese | Q33303164 | ||
| Unwarranted variations in healthcare delivery: implications for academic medical centres | Q33812581 | ||
| Changing clinical behaviour by making guidelines specific | Q35649509 | ||
| Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF | Q36620540 | ||
| Effect of obesity on the leukocyte nadir in women treated with adjuvant cyclophosphamide, methotrexate, and fluorouracil dosed according to body surface area | Q43587855 | ||
| Are medical oncologists biased in their treatment of the large woman with breast cancer? | Q43661609 | ||
| Neutropenia-wise and pound-foolish: safe and effective chemotherapy in massively obese patients | Q43878612 | ||
| Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices | Q44691615 | ||
| Relation between chemotherapy dose, oestrogen receptor expression, and body-mass index. | Q46719661 | ||
| Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy | Q56786457 | ||
| Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541 | Q71778665 | ||
| Should anticancer drug doses be adjusted in the obese patient? | Q72538889 | ||
| Obesity is not associated with increased myelosuppression in patients receiving chemotherapy for breast cancer | Q79433843 | ||
| Undertreatment of obese women receiving breast cancer chemotherapy | Q81850669 | ||
| Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy | Q83357792 | ||
| Formulas for calculating body surface area | Q94039398 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | obesity | Q12174 |
| chemotherapy | Q974135 | ||
| P304 | page(s) | 2159-2165 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice | |
| P478 | volume | 112 |
| Q37263598 | 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study |
| Q36312833 | Association between parity and obesity in Mexican and Mexican-American women: findings from the Ella binational breast cancer study |
| Q35873283 | Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy |
| Q27014939 | Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies |
| Q38121735 | Chemotherapy dosing in overweight and obese patients with cancer |
| Q33384061 | Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2. |
| Q38121736 | Clinical management of obese patients with cancer |
| Q33846184 | Description of Current Practices of Empiric Chemotherapy Dose Adjustment in Obese Adult Patients |
| Q38037349 | Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review |
| Q35748477 | Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies |
| Q36318861 | Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer |
| Q35684496 | Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support |
| Q36426540 | Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project. |
| Q37854751 | The effects of obesity on drug pharmacokinetics in humans |
| Q47174089 | The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). |
| Q36217437 | The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers |
| Q43524982 | Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women |
Search more.